Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mounir Abouzakhm who wrote (300)	5/21/1999 12:43:00 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3559

Anyone can say what ever he want, but we should not forget next: If Schleifer didn't pull out deal with P&G (and it was 50:50 deal with P&G to pay R&D and PI clinical) REGN will today be penny stock. However, none can leave forever on old success, so let see next step. Miljenko

To: Mounir Abouzakhm who wrote (300)	5/23/1999 12:58:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3559

Mounir: Thanks for the comments. With respect to Schleifer, it's certainly not stupidity or arrogance. I like the guy. However, I do feel that he's immersed in "business according to the classic outline for biotech CEOs". That manual is outdated. Hybridon? I attended an IBC conference in '97 on angiogenesis where they were presenting on topical VEGF antisense. I wasn't even close to being impressed. Yeah, one of the sector's classic examples of a company going nowhere from inception. Somebody on the operations (manufacturing) side must have been pretty good, however. Rick